<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6366">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01674803</url>
  </required_header>
  <id_info>
    <org_study_id>BIO-RESORT</org_study_id>
    <nct_id>NCT01674803</nct_id>
  </id_info>
  <brief_title>Comparison of BIOdegradable Polymer and DuRablE Polymer Drug-eluting Stents in an All COmeRs PopulaTion (BIO-RESORT)</brief_title>
  <acronym>BIO-RESORT</acronym>
  <official_title>Comparison of BIOdegradable Polymer and DuRablE Polymer Drug-eluting Stents in an All COmeRs PopulaTion: Randomized Multicenter Trial in an All Comers Population Treated Within thE NeThErlands 3 (TWENTE 3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardio Research Enschede BV</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardio Research Enschede BV</source>
  <oversight_info>
    <authority>Netherlands: Medical Ethics Review Committee (METC)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The introduction of drug-eluting stents (DES) in the treatment of coronary artery disease
      has led to a significant reduction in morbidity. However, the first generation of these
      devices had no positive impact on the mortality after PCI (compared to bare metal stents),
      which was greatly attributed to a somewhat increased incidence of late and very late stent
      thrombosis. Concerns about the role of durable polymers as a potential trigger of
      inflammation and finally adverse events also led to the development of DES with
      biodegradable coatings, which leave after degradation of the coating only a bare metal stent
      in the vessel wall that does not induce an inflammatory response. While such biodegradable
      polymer DES are increasingly used in clinical practice, there is no data available from
      head-to-head comparisons between biodegradable and contemporary third generation durable
      polymer DES.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Target vessel failure (TVF)</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Target vessel failure is a combined endpoint of cardiac death, target vessel related myocardial infarction and clinically driven target vessel revascularization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target lesion failure (TLF)</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Target lesion failure is a combined endpoint of cardiac death, target vessel related myocardial infarction, and clinically driven target lesion revascularization</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">3540</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Angina Pectoris</condition>
  <condition>Angina, Unstable</condition>
  <condition>Myocardial Infarction</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Stenosis</condition>
  <condition>Coronary Restenosis</condition>
  <arm_group>
    <arm_group_label>Orsiro</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Synergy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Resolute Integrity</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Orsiro</intervention_name>
    <description>biodegradable polymer sirolimus eluting stent</description>
    <arm_group_label>Orsiro</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Synergy</intervention_name>
    <description>biodegradable polymer everolimus eluting stent</description>
    <arm_group_label>Synergy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Resolute Integrity</intervention_name>
    <description>durable polymer zotarolimus-eluting stent</description>
    <arm_group_label>Resolute Integrity</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Minimum age of 18 years.

          -  Significant coronary artery disease and lesion(s) eligible for treatment with drug
             eluting stents according to clinical guidelines and/or the operators' judgement.

          -  Capable of providing informed consent.

          -  Patients with all clinical syndromes will be enrolled without any exclusion based on
             number, type, location, or length of lesions to be treated.

        Exclusion Criteria:

          -  Known intolerance to components of one of the stents that will be investigated or
             known intolerance to antithrombotic and/or anticoagulant therapy that prevents
             adherence to dual antiplatelet therapy.

          -  Planned elective surgical procedure necessitating interruption of dual antiplatelet
             therapy during the first 6 months after randomization.

          -  Participation in another randomized drug or device trial before reaching primary
             endpoint.

          -  Adherence to scheduled follow-up is unlikely or life expectancy assumed to be less
             than 1 year.

          -  Known pregnancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>C. von Birgelen, MD,PhD,Prof</last_name>
    <phone>0031534872105</phone>
    <email>cre@mst.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>H. Verheij, RS</last_name>
    <phone>0031534872105</phone>
    <email>cre@mst.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Albert Schweitzer Ziekenhuis</name>
      <address>
        <city>Dordrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>0786541111</phone>
    </contact>
    <investigator>
      <last_name>A. Dirkali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>August 27, 2012</lastchanged_date>
  <firstreceived_date>August 21, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Thorax Centrum Twente</investigator_affiliation>
    <investigator_full_name>prof. C. von Birgelen</investigator_full_name>
    <investigator_title>Professor C. von Birgelen</investigator_title>
  </responsible_party>
  <keyword>drug-eluting stent</keyword>
  <keyword>zotarolimus</keyword>
  <keyword>everolimus</keyword>
  <keyword>sirolimus</keyword>
  <keyword>all comers population</keyword>
  <keyword>target vessel failure</keyword>
  <keyword>coronary artery disease</keyword>
  <keyword>durable polymer</keyword>
  <keyword>biodegradable polymer</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Angina, Unstable</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Coronary Restenosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
